Skip to main content
Premium Trial:

Request an Annual Quote

Veracyte, Acerta Pharma Launch Biopharmaceutical Collaboration

NEW YORK – Genomic testing firm Veracyte has partnered with Acerta Pharma, the hematology research and development arm of AstraZeneca, to provide genomic information that will support Acerta's development of oncology therapeutics. 

Financial and other terms were not disclosed. 

"We are excited to partner with Acerta Pharma and AstraZeneca, global leaders whose innovative medicines are benefiting millions of patients worldwide," Veracyte Chairman and CEO Bonnie Anderson said in a statement. "This collaboration reflects the significant value we can bring to biopharmaceutical companies through our expanding global footprint, as well as our ability to potentially inform diagnosis and treatment decisions in new oncology indications." 

In December, Veracyte acquired the exclusive diagnostics rights to globally license NanoString's nCounter platform and genomic tests in breast cancer and lymphoma 

The Scan

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.

Clinical Trial Participants, Investigators Point to Importance of Clinical Trial Results Reporting in Canadian Study

Public reporting on clinical trial results is crucial, according to interviews with clinical trial participants, investigators, and organizers from three provinces appearing in BMJ Open.

Old Order Amish Analysis Highlights Autozygosity, Potential Ties to Blood Measures

Researchers in BMC Genomics see larger and more frequent runs-of-homozygosity in Old Order Amish participants, though only regional autozygosity coincided with two blood-based measures.

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.